US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Newron Pharmaceuticals Spa. (NP5) 銘柄情報

Newron Pharmaceuticals Spa. (NP5)

12.95

-0.30

(-2.26%)

終了 6月10日 5:00AM

Newron Pharmaceuticals Spa. (NP5) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

12.95

( -2.26% )

買値

12.90

売値

13.00

出来高

1,938

12.85 日の範囲 13.20

7.05 52 週間の範囲 34.15

時価総額

前日終値

13.25

始値

13.20

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

81,847 €

発行済株式数

20,014,585

配当利回り

PER

-20.05

1 株当たり利益 (EPS)

-0.66

歳入

19.13M

純利益

-13.24M

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European... Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.newron.com

本社

Bresso, Italy

設立

1999

Newron Pharmaceuticals Spa. is listed in the Healthcare sector of the Tradegate (DE) with ticker NP5. The last closing price for Newron Pharmaceuticals was 13.25 €. Over the last year, Newron Pharmaceuticals shares have traded in a share price range of 7.05 € to 34.15 €.

Newron Pharmaceuticals currently has 20,014,585 shares in issue. The market capitalisation of Newron Pharmaceuticals is 259.19 € million. Newron Pharmaceuticals has a price to earnings ratio (PE ratio) of -20.05.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-1.1	-7.82918149466	14.05	14.2	12.8	7045	13.36593283	DE
4	-2.6	-16.7202572347	15.55	16.75	12.8	4801	14.55672103	DE
12	-4.47	-25.6601607348	17.42	19	12.75	5202	15.72058842	DE
26	-7.65	-37.1359223301	20.6	34.15	12.75	6861	21.34744266	DE
52	4.45	52.3529411765	8.5	34.15	7.05	6053	17.46378837	DE
156	8.53	192.986425339	4.42	34.15	4.2	7352	10.87327238	DE
260	10.6	451.063829787	2.35	34.15	1.13	5645	9.66952099	DE

NP5 - Frequently Asked Questions (FAQ)

What is the current Newron Pharmaceuticals Spa. share price?

The current share price of Newron Pharmaceuticals Spa. is 12.95 €

How many Newron Pharmaceuticals Spa. shares are in issue?

Newron Pharmaceuticals Spa. has 20,014,585 shares in issue

What is the market cap of Newron Pharmaceuticals Spa.?

The market capitalisation of Newron Pharmaceuticals Spa. is EUR 259.19M

What is the 1 year trading range for Newron Pharmaceuticals Spa. share price?

Newron Pharmaceuticals Spa. has traded in the range of 7.05 € to 34.15 € during the past year

What is the PE ratio of Newron Pharmaceuticals Spa.?

The price to earnings ratio of Newron Pharmaceuticals Spa. is -20.05

What is the cash to sales ratio of Newron Pharmaceuticals Spa.?

The cash to sales ratio of Newron Pharmaceuticals Spa. is 14.46

What is the registered address of Newron Pharmaceuticals Spa.?

The registered address for Newron Pharmaceuticals Spa. is Via Antonio Meucci 3, Bresso, Milan, 20091

What is the Newron Pharmaceuticals Spa. website address?

The website address for Newron Pharmaceuticals Spa. is www.newron.com

Which industry sector does Newron Pharmaceuticals Spa. operate in?

Newron Pharmaceuticals Spa. operates in the Biotechnology & Life Sciences sector

quigley24

quigley24 3分前

Duke Knockem

Duke Knockem 3分前

I know that I have made my research, I have been taking screenshot of all the person's claiming his death on Twitter and if George is not deceased everyone will be facing legal charges

GoodGuyBill

GoodGuyBill 3分前

I wasn’t “picking on” anyone. I used an example where the facts are documented and not in dispute — that’s why it works as a comparison. The point wasn’t politics; it was behavior. Some people keep repeating claims long after the evidence has soundly and irrefutably disproven them.

Th

HoldHigh

HoldHigh 6分前

From an AI bot.

Trulieve Cannabis Corp. is set to ring the opening bell at the New York Stock Exchange (NYSE) on June 10, 2026. This event marks a significant milestone as Trulieve becomes the first U.S. cannabis company to be listed on a major American exchange.
Significance

satter

The company is prepared to deceive/misrepresent/Bs, as there is no case, no court, just parrot robots ready to spew/pump their nonsense.

Know anyone ( parrot robot ) who would do that? ( spew thier nonsense ) 🤔

haha11

UPR0....SPXU....60...10Ds. SPYI 60 10Ds (HI. INCOME)

$UPRO 60.....
https://stockcharts.com/sc3/ui/?s=UPRO&p=60&yr=0&mn=0&dy=10&id=p49774974308&a=234724271

$SPXU...60..
https://stockcharts.com/sc3/ui/?s=SPXU&p=60&yr=0&mn=0&dy=10&id=p49774974308&a=2347242

northam43

northam43 8分前

#1.2 SPX Cycles Expanded Report: Current Cycles Between Cycles (CCBC) is -39 (very bearish). Extreme Overdue: 60 min (60-S-1, 60-1) Daily (D-S-1) Weekly (W-1). No OB. No OS. Tomorrow possibility of a 60-E-1 & 4th UPRO Buy Signal.

https://investorshub.advfn.com/uimage/uploads/2026/6/9

northam43

northam43 8分前

#1.2 SPX Cycles Expanded Report: Current Cycles Between Cycles (CCBC) is -39 (very bearish). Extreme Overdue: 60 min (60-S-1, 60-1) Daily (D-S-1) Weekly (W-1). No OB. No OS. Tomorrow possibility of a 60-E-1 & 4th UPRO Buy Signal.

https://investorshub.advfn.com/uimage/uploads/2026/6/9

US Market News

US Market News 10分前

Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of DirectorsJune 9, 2026 8:30 PM
Business Wire Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated

wronginvestor

wronginvestor 10分前

satter - Whats your view. I cannot see how the Silver mine deal can complete based on where we are now. Actually I believe they can go after the silver mine deal now without waiting for the dismissal of the appeal.

I guess what I am surprised about is that they have not tried to do th

CharlotteEmma

CharlotteEmma 11分前

From public ledgers to mixers and legal recovery – what every victim needs to know
If you have fallen victim to a Bitcoin scam, you are likely asking one urgent question: Can my stolen Bitcoin be traced? The short answer is yes – but the process is complex, requires specialized tools, and doe

trunkmonk

trunkmonk 11分前

I know you’re almost never right. It never has been it never will be, if clarity is not passed. The SEC thing is over. You know that, yeah, you posted it here as if it means anything. Shorts
Should be ashamed of themselves

DJPele

DJPele 13分前

flipper44

flipper44 14分前

That’s why I’m asking for confirmation. I asked about opening of leuk clinic timeline (licensing/cert), and somebody rushes in with maa approval a couple hours later.

wronginvestor

wronginvestor 15分前

Read AI's view of the silver mine deal once Judgement is confirmed. Even if Hiru has made the second payment, the deal is really at risk and likely to fall through.

Hiru PR for sure put EMUS on alert that the deal is at risk, regardless of payments being made.

1. The M

Genz2

https://www.securityweek.com/wave-systems-signs-15-year-license-agreement-samsung/

Survivor2012

Survivor2012 17分前

Did GZ say "one to three months" -- I think not, remember, no MAA updates will be provided per LP. Likely, an inference per Gary based on his conversation with GZ, IMHO.

haha11

haha11 17分前

TQQQ SQQQ UDOW.....60.....10Ds......

TQQQ...60...
https://stockcharts.com/sc3/ui/?s=TQQQ&p=60&yr=0&mn=0&dy=10&id=p49774974308&a=234724271

$SQQQ..
https://stockcharts.com/sc3/ui/?s=SQQQ&p=60&yr=0&mn=0&dy=10&id=p49774974308&a=234724271

Tamboo

Tamboo 17分前

Any information from Mr Jaywright about these rumours

northam43

northam43 18分前

Report #9 SPX Cycles 12 Month Range Forecast: Today a new low for the month.
The projected high range is based on the current year 60 min cycle average.
The projected low range is based on the 60 min cycle averages from 2011 to present

https://investorshub.advfn.com/uima

northam43

northam43 19分前

Report #9 SPX Cycles 12 Month Range Forecast: Today a new low for the month.
The projected high range is based on the current year 60 min cycle average.
The projected low range is based on the 60 min cycle averages from 2011 to present

https://investorshub.advfn.com/uima

SCAMBUSTERKING

SCAMBUSTERKING 19分前

Big eyes you say... seems fitting people with extra chrom would be interested ina Jakey scam thinking its a good investement.

mascale

mascale 20分前

"Company is prepared to challenge. . . ."

uplata

uplata 21分前

Take a look his spy ta not bad.

https://youtu.be/bjV3kDpYFEQ

Newron Pharmaceuticals

Transcontinental B (PK)

Rockwell Automation

Tidal Trust III

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。